BR112017008721A2 - formulação líquida injetável, composição de liberação controlada, e, métodos para entrega prolongada de buprenorfina, para formação de uma composição de liberação controlada e para tratamento ou profilaxia de um sujeito animal humano ou não humano. - Google Patents

formulação líquida injetável, composição de liberação controlada, e, métodos para entrega prolongada de buprenorfina, para formação de uma composição de liberação controlada e para tratamento ou profilaxia de um sujeito animal humano ou não humano.

Info

Publication number
BR112017008721A2
BR112017008721A2 BR112017008721A BR112017008721A BR112017008721A2 BR 112017008721 A2 BR112017008721 A2 BR 112017008721A2 BR 112017008721 A BR112017008721 A BR 112017008721A BR 112017008721 A BR112017008721 A BR 112017008721A BR 112017008721 A2 BR112017008721 A2 BR 112017008721A2
Authority
BR
Brazil
Prior art keywords
controlled release
release composition
treatment
human
buprenorphine
Prior art date
Application number
BR112017008721A
Other languages
English (en)
Inventor
Tiberg Fredrik
Harwigsson Ian
Johnsson Markus
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52103459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017008721(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of BR112017008721A2 publication Critical patent/BR112017008721A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente invenção provê uma formulação líquida injetável com liberação controlada compreendendo: a) uma matriz lipídica de liberação controlada compreendendo pelo menos 50% de triacil-lipídios; b) pelo menos um solvente orgânico contendo oxigênio; c) pelo menos 16% em peso de pelo menos um agente ativo selecionado dentre buprenorfina e seus sais, calculado como base livre de buprenorfina. a invenção também provê um método para o tratamento de dor, para terapia de manutenção de opioides ou para o tratamento da dependência de opioides por desintoxicação e/ou manutenção ou para o tratamento ou profilaxia dos sintomas de abstinência de opioides e/ou de abstinência de cocaína por injeção de tal composição líquida.
BR112017008721A 2014-10-27 2015-10-27 formulação líquida injetável, composição de liberação controlada, e, métodos para entrega prolongada de buprenorfina, para formação de uma composição de liberação controlada e para tratamento ou profilaxia de um sujeito animal humano ou não humano. BR112017008721A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1419091.2A GB201419091D0 (en) 2014-10-27 2014-10-27 Formulations
PCT/EP2015/074901 WO2016066655A1 (en) 2014-10-27 2015-10-27 Injectable buprenorphine formulation

Publications (1)

Publication Number Publication Date
BR112017008721A2 true BR112017008721A2 (pt) 2018-01-30

Family

ID=52103459

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017008721A BR112017008721A2 (pt) 2014-10-27 2015-10-27 formulação líquida injetável, composição de liberação controlada, e, métodos para entrega prolongada de buprenorfina, para formação de uma composição de liberação controlada e para tratamento ou profilaxia de um sujeito animal humano ou não humano.

Country Status (17)

Country Link
US (2) US20180015031A1 (pt)
EP (1) EP3212168A1 (pt)
JP (1) JP6768648B2 (pt)
KR (2) KR20170072237A (pt)
CN (1) CN107205920B (pt)
AU (1) AU2015340661B2 (pt)
BR (1) BR112017008721A2 (pt)
CA (1) CA2964045C (pt)
CL (1) CL2017001024A1 (pt)
EA (1) EA033935B1 (pt)
GB (1) GB201419091D0 (pt)
IL (1) IL251413B2 (pt)
MX (1) MX2017005461A (pt)
MY (1) MY183540A (pt)
SG (1) SG11201703158WA (pt)
TW (1) TW201625250A (pt)
WO (1) WO2016066655A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61377B1 (sr) 2012-07-26 2021-02-26 Camurus Ab Opioidne formulacije
CA3015557C (en) 2014-11-07 2019-07-16 Indivior Uk Limited The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders
PT3512518T (pt) * 2016-09-13 2023-01-27 Alar Pharmaceuticals Inc Formulações de buprenorfina de libertação prolongada
PT3512495T (pt) 2016-09-15 2023-02-15 Camurus Ab Formulações análogas a prostaciclina
CN109789214B (zh) 2016-09-27 2022-06-28 卡姆拉斯公司 包含edta烷基铵盐的混合物和制剂
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
TWI819756B (zh) * 2021-08-20 2023-10-21 大陸商蘇州恩華生物醫藥科技有限公司 包含塞納布啡的藥物組合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1263760C (zh) * 2002-11-12 2006-07-12 财团法人奇美医院 新颖的丁丙诺啡酯衍生物及其制备方法，以及长效作用镇痛药学组合物
DE60224288T2 (de) * 2002-11-25 2009-04-16 Chi Mei Foundation Medical Center Buprenorphinesterderivate, Verfahren zu ihrer Herstellung, und langwirksame analgetische Arzneimittel
ATE401054T1 (de) * 2004-06-04 2008-08-15 Camurus Ab Flüssige depotformulierungen
MX2011000629A (es) * 2008-07-17 2011-04-26 Merial Ltd Formulaciones analgesicas inyectables de larga duracion para animales.
GB2481018B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
RS61377B1 (sr) * 2012-07-26 2021-02-26 Camurus Ab Opioidne formulacije
CN103142458B (zh) * 2013-01-22 2015-09-09 莱普德制药有限公司 无成瘾性镇痛缓释递药系统的组方与制备方法

Also Published As

Publication number Publication date
CA2964045A1 (en) 2016-05-06
US20210308041A1 (en) 2021-10-07
EA201790721A1 (ru) 2017-09-29
KR20230039767A (ko) 2023-03-21
US20180015031A1 (en) 2018-01-18
WO2016066655A1 (en) 2016-05-06
CN107205920B (zh) 2021-05-25
TW201625250A (zh) 2016-07-16
JP6768648B2 (ja) 2020-10-14
MY183540A (en) 2021-02-25
IL251413A0 (en) 2017-05-29
EP3212168A1 (en) 2017-09-06
AU2015340661A1 (en) 2017-04-20
SG11201703158WA (en) 2017-05-30
IL251413B1 (en) 2023-01-01
JP2017532354A (ja) 2017-11-02
CA2964045C (en) 2023-03-07
KR20170072237A (ko) 2017-06-26
EA033935B1 (ru) 2019-12-11
AU2015340661B2 (en) 2018-04-26
MX2017005461A (es) 2018-01-17
NZ730521A (en) 2023-11-24
CN107205920A (zh) 2017-09-26
GB201419091D0 (en) 2014-12-10
KR102541281B1 (ko) 2023-06-13
CL2017001024A1 (es) 2017-11-10
IL251413B2 (en) 2023-05-01

Similar Documents

Publication Publication Date Title
BR112017008721A2 (pt) formulação líquida injetável, composição de liberação controlada, e, métodos para entrega prolongada de buprenorfina, para formação de uma composição de liberação controlada e para tratamento ou profilaxia de um sujeito animal humano ou não humano.
CL2019001565A1 (es) Composición farmacéutica para prevenir o tratar el cáncer, comprendiendo el polímorfo cristalino del hexoxido tetraarsénico.
CL2019001369A1 (es) Composición farmacéutica para prevenir o tratar el cáncer de mama, incluido el polimorfo cristalino del hexoxido tetraarsenico y el método para producirlo.
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
DOP2015000241A (es) Compuestos de biaril-amida como inhibidores de cinasa
BR112017002221A2 (pt) 2-(morfolin-4-il)-1,7-naftiridinas
AR093247A1 (es) Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo
BR112016003201A2 (pt) inibidores de grp94 seletivos e usos dos mesmos
ECSP17021897A (es) Compuestos y composiciones como inhibidores de quinasa raf
AR090491A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
BR112016002171A2 (pt) método, composição estéril e injetável e método para preparar uma composição estéril e injetável
CL2020000747A1 (es) Formulaciones de niraparib.
MX2016004035A (es) Formulaciones de espiro-isoxazolina de accion prolongada.
MX2015012559A (es) Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson.
BR112019005351A2 (pt) terapia combinada com agonistas de cnp de liberação controlada
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
CR20150505A (es) Derivado de dihidropiridazin-3,5-diona
BR112016024020A8 (pt) composição farmacêutica
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
AR109012A1 (es) Sistema de administración transdérmica que contiene galantamina o sales de esta
AR100444A1 (es) Uso de palmitoiletanolamida en combinación de opioides

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]